MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-10-2026
Sonoma Pharmaceuticals Total Assets 2011-2026 | SNOA
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Sonoma Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.7 M | 14.7 M | 16.2 M | 18.8 M | 15 M | 14.6 M | 14.4 M | 19.2 M | 25.5 M | 13.8 M | 15 M | 20.8 M | 12.6 M | 7.84 M | 8.66 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.5 M | 7.84 M | 15.4 M |
Quarterly Total Assets Sonoma Pharmaceuticals
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.6 M | 13.9 M | 14.6 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | 14.7 M | 14.6 M | 13.6 M | 15.9 M | 16.2 M | 13.9 M | 15 M | 17.2 M | 18.8 M | 19.3 M | 19.8 M | 14.1 M | 15 M | 18.2 M | 18.1 M | 18.1 M | 18.7 M | 16.5 M | 16.1 M | 16.9 M | 14.4 M | 17 M | 14.3 M | 16.6 M | 19.2 M | 18.4 M | 20.2 M | 22.4 M | 25.5 M | 27.5 M | 9.24 M | 11.3 M | 13.8 M | 12.1 M | 13.6 M | 14.2 M | 15 M | 11.8 M | 18.4 M | 19.9 M | 20.8 M | 9.84 M | 8.88 M | 10.6 M | 12.6 M | 11.8 M | 13.4 M | 9.69 M | 7.84 M | 8.98 M | 7.76 M | 9.21 M | 8.66 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 27.5 M | 7.76 M | 15 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Assertio Holdings
ASRT
|
267 M | $ 18.03 | 0.06 % | $ 115 M |  USA |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
29.7 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 3.26 | 5.5 % | $ 45.8 M | USA |
 |
Cronos Group
CRON
|
1.93 B | $ 2.57 | -0.39 % | $ 1.33 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.64 | 0.45 % | $ 2.06 B | Canada |
 |
Harrow Health
HROW
|
399 M | $ 36.64 | 1.98 % | $ 1.35 B | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 3.36 | -2.04 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.03 | -1.43 % | $ 111 M | Canada |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.4 | -0.36 % | $ 402 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
289 M | - | - | $ 193 M | Canada |
 |
Jupiter Wellness
JUPW
|
41 M | - | - | $ 33.6 M | USA |
 |
Relmada Therapeutics
RLMD
|
94 M | $ 7.37 | 1.1 % | $ 291 M | USA |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
226 M | $ 4.35 | 1.76 % | $ 280 M | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 8.0 | 0.5 % | $ 410 M | USA |
 |
Sundial Growers
SNDL
|
1.34 B | $ 1.37 | -3.87 % | $ 3.37 M | Canada |
 |
Tilray
TLRY
|
4.31 B | $ 6.49 | -1.29 % | $ 4.01 B | Canada |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 2.37 | -0.35 % | $ 312 M | USA |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 24.3 | 2.14 % | $ 1.12 B | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.42 | 1.68 % | $ 326 M | USA |
 |
Viatris
VTRS
|
50 B | $ 13.53 | 0.45 % | $ 16.2 B | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 0.7 | 4.36 % | $ 3.02 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
59 M | $ 1.02 | 2.0 % | $ 50.9 M | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
233 M | $ 7.92 | -1.25 % | $ 693 M | USA |
 |
Zomedica Corp.
ZOM
|
127 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
57.1 M | $ 0.91 | 0.02 % | $ 32.7 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
31 M | $ 0.65 | 3.14 % | $ 2.79 M |  China |
 |
TherapeuticsMD
TXMD
|
37.7 M | $ 2.03 | -1.93 % | $ 23.5 M | USA |